Announcements Trials
Browse Landscape

Phase

Phase 2 1Phase 1/2 1

Status

Unknown 1Completed 1

Sponsor Class

OTHER 2

Study Type

Interventional 2

Sponsor

Cancer Type

Gastrointestinal 2

Conditions

Carcinoma, Non-Small-Cell Lung 35Carcinoma, Hepatocellular 28Stomach Neoplasms 12Neoplasm Metastasis 12Nasopharyngeal Carcinoma 11Neoplasms 10Esophageal Neoplasms 10Melanoma 8Esophageal Squamous Cell Carcinoma 8Colorectal Neoplasms 8Recurrence 7Lung Neoplasms 7Breast Neoplasms 7Biliary Tract Neoplasms 7Triple Negative Breast Neoplasms 6Small Cell Lung Carcinoma 5Rectal Neoplasms 5Pancreatic Neoplasms 5Head and Neck Neoplasms 5Cholangiocarcinoma 5Squamous Cell Carcinoma of Head and Neck 4Locally Advanced Rectal Cancer 4Colonic Neoplasms 4Carcinoma, Renal Cell 4Advanced NSCLC 4Urinary Bladder Neoplasms 3Sarcoma 3Liver Neoplasms 3Leukemia, Myeloid, Acute 3Hyperthermia 3

Interventions

Capecitabine 6Irinotecan 5Fluorouracil 5Cisplatin 5Oxaliplatin 4Leucovorin 4Gemcitabine 4apatinib 3Sorafenib 3Bevacizumab 3tislelizumab 2pembrolizumab 2Sunitinib 2Radiotherapy 2Paclitaxel 2Immune Checkpoint Inhibitors 2Cyclophosphamide 2Cetuximab 2Aspirin 2Ascorbic Acid 2130-nm albumin-bound paclitaxel 2spartalizumab 1sintilimab 1regorafenib 1pyrotinib 1pemigatinib 1lutetium Lu 177 dotatate 1huachansu 1halofantrine 1guadecitabine 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
OTHER × Digestive System Neoplasms × Immune Checkpoint Inhibitors × Clear all
NCT06022692 2023-09-05

HEAIS001

Zhejiang Hospital

Phase 1/2 Completed
18 enrolled
Gastrointestinal

Hyperthermia, Digestive System Neoplasms

NCT05913661 2023-06-22

Pemigatinib Combined With PD-1 Inhibitor in Unresectable or Metastatic Intrahepatic Cholangiocarcinoma

Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University

Phase 2 Unknown
30 enrolled
Gastrointestinal

Carcinoma, Digestive System Neoplasms, Cholangiocarcinoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡